Overview

The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Hav

Status:
Completed

Trial end date:
2015-07-22

Target enrollment:

Participant gender:

Summary

The primary objective is to compare the efficacy of UMEC/VI Inhalation Powder (62.5/25 mcg) once-daily with tiotropium (18 mcg) once-daily over 12 weeks for the treatment of subjects with COPD who have received tiotropium and continue to have symptoms while on tiotropium.

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Muscarinic Antagonists
Tiotropium Bromide